Table 6 |
|||
|
Efficacy outcome reporting for each included intervention |
|||
|
Intervention |
|||
|
|
|||
|
Pregabalin |
Lidocaine plaster |
Duloxetine |
|
|
|
|||
|
Mean Pain Scores-No. studies (no. patients receiving the intervention)+ reporting reduction in mean pain scores compared to baseline |
|||
|
|
|||
|
No. studies reporting data for any pain intensity outcome |
7 |
3 |
1 |
|
|
|||
|
McGill questionnaire |
2* (109) |
||
|
|
|||
|
Pain reduction measured by VRS |
2* (81) |
||
|
|
|||
|
Pain intensity measured by NRS |
1* (30) |
1NR (32) |
|
|
|
|||
|
Pain intensity measured by BPI |
2* (73) |
||
|
|
|||
|
Pain score measured by NPS-10, NPS-8 and NPS-4 |
1* (71) |
||
|
|
|||
|
Pain intensity measured by present pain intensity (PPI) |
1* (81) |
||
|
|
|||
|
Percentage pain score reduction |
1NR (16) |
||
|
|
|||
|
Pain severity measured by VAS |
1* (18) |
||
|
|
|||
|
Quality of life-No. studies (no. patients receiving the intervention)+ reporting improvements in quality of life compared to baseline |
|||
|
|
|||
|
No. studies reporting data for any quality of life outcome |
4 |
1 |
0 |
|
|
|||
|
SF-MPQ total, sensory and affective score |
1* |
||
|
|
|||
|
Quality of life measured by the SF-12 |
1* (55) |
||
|
|
|||
|
Sleep interference measured by NRS |
1* (55), 1NS (30) |
||
|
|
|||
|
Quality of sleep measured by VRS |
1* (28) |
||
|
|
|||
|
Quality of sleep (instrument not reported) |
1* (3) |
||
|
|
|||
|
Inference of mood measured by VRS |
1* (28) |
||
|
|
|||
|
Daily activity measured by VRS |
1* (28) |
||
|
|
|||
|
Function interference measured by NRS |
1* (30) |
||
|
|
|||
|
Psychological stress measured by the Short Questionnaire on Current Burden |
1* (55) |
||
|
|
|||
|
Pain associated distress measured by NRS |
1* (30) |
||
|
|
|||
|
PGIC |
1* (18) |
||
|
|
|||
|
Responders-No. studies (no. patients receiving the intervention)+ reporting data for outcome |
|||
|
|
|||
|
No. studies reporting data for any pain relief outcome |
4 |
4 |
0 |
|
|
|||
|
Complete pain relief |
1 (53) |
2 (48) |
|
|
|
|||
|
range of percentages reported |
25% |
13-22% |
|
|
|
|||
|
A lot of pain relief |
2 (48) |
||
|
|
|||
|
range of percentages reported |
25-34% |
||
|
|
|||
|
Moderate pain relief |
2 (48) |
||
|
|
|||
|
range of percentages reported |
33-44% |
||
|
|
|||
|
Pain reduction of ≥ 50% |
3 (158) |
2 (7) |
|
|
|
|||
|
range of percentages reported |
33-49% |
100%a |
|
|
|
|||
|
Pain reduction 10-50% |
2 (105) |
1 (33) |
|
|
|
|||
|
range of percentages reported |
17%b |
NRc |
|
|
|
|||
|
Non-responders |
3 (132) |
2 (52) |
|
|
|
|||
|
range of percentages reported |
26-46% |
6-20% |
|
|
|
|||
|
*Statistically significant; NS-not statistically significant; NR-statistical significance not reported. +Numbers of patients receiving the intervention of interest. aTwo case studies of 3 and 4 patients: the former reported all patients achieved 50% reduction in pain score, the latter reported improvements in all patients in an inconsistent manner. bOne study reported that 4 of 24 patients achieved pain relief of 10-25%. The second study reported 38 out of 78 evaluable patients experienced ≥ 30% reduction in pain from baseline. cOne study stated that patients experienced pain relief of 10%-50%, however it was unclear whether this referred to all patients. |
|||
|
Plested et al. BMC Neurology 2010 10:116 doi:10.1186/1471-2377-10-116 |
|||
